HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Polyacrylamide Use In Cosmetics Safe With Finished Product Limits – CIR

This article was originally published in The Rose Sheet

Executive Summary

Polyacrylamide is safe for use in cosmetics when the acrylamide monomer concentration in finished products is below 2.8 ppm, the Cosmetic Ingredient Review Expert Panel tentatively determined at its meeting in Washington, D.C. Sept. 10-11

You may also be interested in...



CERHR Expert Panel To Review Acrylamide Safety

Human exposure to acrylamide through dermal contact with cosmetics and other consumer products is possible because the polyacrylamide used in these products may contain free acrylamide, the National Toxicology Program Center for the Evaluation of Risks to Human Reproduction states in a 1draft report on the chemical

CERHR Expert Panel To Review Acrylamide Safety

Human exposure to acrylamide through dermal contact with cosmetics and other consumer products is possible because the polyacrylamide used in these products may contain free acrylamide, the National Toxicology Program Center for the Evaluation of Risks to Human Reproduction states in a 1draft report on the chemical

Polyacrylamide Limits In Cosmetics Endorsed By CTFA

Polyacrylamide limits of 2 ppm acrylamide monomer in leave-on cosmetics and 5 ppm acrylamide monomer in rinse-off products were supported by the Cosmetic, Toiletry and Fragrance Association at the Cosmetic Ingredient Review Expert Panel meeting in Washington, D.C. Nov. 29-30

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel